Market Place
Sourcing Support
Vanda Pharma Launches NEREUS for U.S. Motion Sickness
01 May 2026 //
PR NEWSWIRE
Anaptys Completes Separation of First Tracks Biotherapeutics
20 Apr 2026 //
GLOBENEWSWIRE
Vanda Pharma Urges FDA To Remove Proposal Extending Drug Review
09 Apr 2026 //
PR NEWSWIRE
Vanda Secures Long-Awaited FDA Hearing In Jet Lag Approval bid
05 Mar 2026 //
FIERCE PHARMA
Vanda Secures Long-Awaited FDA Hearing In Jet Lag Approval Bid
04 Mar 2026 //
FIERCE PHARMA
FDA Grants Landmark Hearing For HETLIOZ In Jet Lag Disorder
03 Mar 2026 //
PR NEWSWIRE
US FDA Approves Vanda`s Antipsychotic Pill, Shares Climb
23 Feb 2026 //
REUTERS
Vanda Pharma Reveals 2025 Q4 & Full-Year Financials
11 Feb 2026 //
PR NEWSWIRE
Vanda Pharma to Report Q4, FY 2025 Results Feb. 11, 2026
04 Feb 2026 //
PR NEWSWIRE
Vanda Pharma Announces FDA Approval of NEREUS for Motion Sickness
30 Dec 2025 //
PR NEWSWIRE
Vanda Pharma Joins J.P. Morgan Healthcare Conference
11 Dec 2025 //
PR NEWSWIRE
FDA Lifts Partial Hold on Motion Sickness Drug
04 Dec 2025 //
PR NEWSWIRE
Vanda Pharma Updates Tradipitant for Motion Sickness
28 Nov 2025 //
PR NEWSWIRE
Vanda`s Tradipitant Effective in Preventing GLP-1-Induced Nausea
18 Nov 2025 //
PR NEWSWIRE
Vanda Pharma To Participate In Stifel 2025 Healthcare Conf
05 Nov 2025 //
PR NEWSWIRE
Vanda Pharma Reveals Q3 2025 Financials Result
29 Oct 2025 //
PR NEWSWIRE
Vanda Pharma To Report Q3 2025 Financial Results On Oct 29, 2025
22 Oct 2025 //
PR NEWSWIRE
Vanda Pharma Named Jersey Patch Partner of New York Islanders
08 Oct 2025 //
PR NEWSWIRE
Vanda, FDA Reach `Collaborative Framework` After Disputes
02 Oct 2025 //
FIERCE PHARMA
Vanda Pharmaceuticals Announces Collaborative Framework
01 Oct 2025 //
PR NEWSWIRE
Vanda Pharma Publishes Study On Hetlioz® For Insomnia In PLOS One
25 Sep 2025 //
PR NEWSWIRE
Vanda Pharmaceuticals to Participate in September 2025 Investor
28 Aug 2025 //
PR NEWSWIRE
Federal Appeals Court overturns FDA, approves Vanda`s Hetlioz
18 Aug 2025 //
PR NEWSWIRE
Vanda Touts `landmark` Win Over FDA in Years-Long Dispute
18 Aug 2025 //
FIERCE PHARMA
Vanda Pharmaceuticals` Q2 2025 Financial Results Released
31 Jul 2025 //
PR NEWSWIRE
Vanda Pharmaceuticals to Present at 2025 ASCP Meeting
27 May 2025 //
PR NEWSWIRE
Vanda Pharmaceuticals to Join Mizuho Neuro & Ophthalmology Summit
16 May 2025 //
PR NEWSWIRE
Vanda files Bysanti NDA, FDA decision in early 2026
05 May 2025 //
PR NEWSWIRE
Vanda Pharmaceuticals to Announce Q1 2025 Results on May 7
05 May 2025 //
PR NEWSWIRE
Vanda sues FDA over months-long hearing delay
23 Apr 2025 //
FIERCE BIOTECH
Vanda Sues Fda For Right To Promote Off-Label Drug Use
14 Apr 2025 //
FIERCE PHARMA
Vanda Pharmaceuticals at 2025 AAN Annual Meeting
07 Apr 2025 //
PR NEWSWIRE
Vanda Phama Announces Submission of an NDA to the FDA for Bysanti
31 Mar 2025 //
PR NEWSWIRE
Vanda Pharma Reports Q4 & Full Year 2024 Financial Results
13 Feb 2025 //
PR NEWSWIRE
Vanda Pharma to Announce Q4 & Full Year 2024 Financial Results
05 Feb 2025 //
PR NEWSWIRE
Vanda Pharma Accepts FDA for Hearing on NDA for Tradipitant
27 Jan 2025 //
PR NEWSWIRE
Vanda loses constitutional fight over FDA`s drug with competitors
23 Jan 2025 //
ENDPTS
Vanda Highlights FDA Review Issues for Gastroparesis NDA
08 Jan 2025 //
PR NEWSWIRE
Vanda Pharma Announce Participation at Nov 2024 Investor Conf
12 Nov 2024 //
PR NEWSWIRE
Vanda Pharmaceuticals Reports Q3 2024 Financial Results
06 Nov 2024 //
PR NEWSWIRE
Vanda Announces Q3 2024 Financial Results on Nov 6, 2024
30 Oct 2024 //
PR NEWSWIRE
Vanda Pharmaceuticals rejects Cycle Pharma`s second takeover offer
15 Oct 2024 //
REUTERS
Vanda Pharmaceuticals To Attend Cantor Global Healthcare Conference
11 Sep 2024 //
PR NEWSWIRE
Vanda Pharma to Participate in H.C. Wainwright Global Investment Conference
04 Sep 2024 //
PR NEWSWIRE
Vanda To Participate In Wells Fargo Healthcare Conference
29 Aug 2024 //
PR NEWSWIRE
Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results
31 Jul 2024 //
PR NEWSWIRE
Vanda Pharmaceuticals To Report Q2 2024 Results On July 31
26 Jul 2024 //
PR NEWSWIRE
Court Allows Vanda`s HETLIOZ Patent Lawsuit Against Teva And Apotex
01 Jul 2024 //
PR NEWSWIRE
Vanda Completes Ponvory Marketing Authorization Transfer To FDA
30 May 2024 //
PR NEWSWIRE
Fanapt Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study
19 Dec 2022 //
PRNEWSWIRE
Vanda Pharmaceuticals Provides an Update to HETLIOZ ANDA Litigation Appeal
16 Dec 2022 //
PRNEWSWIRE
Teva, Apotex prevail over Vanda in patent infringement case
15 Dec 2022 //
FIERCEPHARMA
Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Litigation
13 Dec 2022 //
PRNEWSWIRE
Vanda Pharma Reports Results in a Phase II Clinical Study of VQW-765
02 Dec 2022 //
PRNEWSWIRE
Vanda appeals to FDA again, insisting on sNDA hearing in jet lag drug saga
17 Nov 2022 //
ENDPTS
Vanda Pharmaceuticals Reports Third Quarter 2022 Financial Results
02 Nov 2022 //
PRNEWSWIRE
Vanda to Announce Third Quarter 2022 Financial Results on November 2, 2022
27 Oct 2022 //
PRNEWSWIRE
Vanda Pharma Announces Orphan Drug Designation Granted for VPO-227
21 Oct 2022 //
PRNEWSWIRE
CDER strikes back at Vanda, discloses rationale behind 2019 sNDA rejection
10 Oct 2022 //
ENDPTS
